NASDAQ
BMGL
Last Price
US $8.12
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Basel Medical Group Ltd Ordinary Shares cash flow to debt ratio of -127.04% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Basel Medical Group Ltd Ordinary Shares's free cash flow has decreased -275.86% from $2.50M last year to $-4.40M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Basel Medical Group Ltd Ordinary Shares's debt to equity ratio is 1.57, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Basel Medical Group Ltd Ordinary Shares's debt has increased relative to shareholder equity from 0.57 last year to 1.57 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Basel Medical Group Ltd Ordinary Shares has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Basel Medical Group Ltd Ordinary Shares's interest coverage ratio is -14.25, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Basel Medical Group Ltd Ordinary Shares's profit margin has decreased (-428.06%) in the last year from 20.62% to -67.66%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Basel Medical Group Ltd Ordinary Shares's short-term assets of $13.12M exceed its short-term liabilities of $10.69M
Decreasing performance - ROA.
Basel Medical Group Ltd Ordinary Shares's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Basel Medical Group Ltd Ordinary Shares's return on equity of -173.64%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Basel Medical Group Ltd Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Basel Medical Group Ltd Ordinary Shares had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings
Decreasing performance - Free cash flow.
Basel Medical Group Ltd Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Basel Medical Group Ltd Ordinary Shares has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Basel Medical Group Ltd Ordinary Shares's yearly earnings has decreased -683.15% since last year from $2.07M to $-12.09M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Basel Medical Group Ltd Ordinary Shares's yearly revenue has increased 12.63% since last year from $10.05M to $11.32M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -26.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Basel Medical Group Ltd Ordinary Shares's 3-year revenue CAGR of 2.03% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
Basel Medical Group Ltd Ordinary Shares had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
Basel Medical Group Ltd Ordinary Shares had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Basel Medical Group Ltd Ordinary Shares has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Basel Medical Group Ltd Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Basel Medical Group Ltd Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Basel Medical Group Ltd Ordinary Shares has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Basel Medical Group Ltd Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Basel Medical Group Ltd Ordinary Shares has a price-to-book ratio of 1.95x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Basel Medical Group Ltd Ordinary Shares has a price-to-sales ratio of 0.89x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $8.12
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.